AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026 Initial data indicates significantly higher tracer uptake in patients with ...

A new gene therapy, Celosia's CTx1000, is now being tested for ALS in a small clinical trial in Australia. The one-time treatment targets toxic TDP-43 protein clumps, a key driver of most cases of ALS ...

Learn more AC Immune SA (NASDAQ:ACIU) is one of the 7 Best Strong Buy European Stocks to Invest In. On April 7, 2026, Leerink ...

Doctors are only just getting to grips with LATE – a newly recognised form of cognitive decline behind up to one in five ...

One distinct hallmark of ALS is the dysfunction of a tiny protein called TDP-43. At the Les Turner ALS Center at Northwestern Medicine, a trio of researchers formed a unique hypothesis: What if the ...

KOANEWA is a first-in-human, open-label Phase 1b clinical trial, designed to evaluate the safety and tolerability of a single administration of CTx1000 in participants with ALS [ClinicalTrials.gov].

Steve "Mongo" McMichael, the Chicago Bears legend and Hall of Famer who died last year after a battle with ALS, was diagnosed ...

McMichael's widow Misty said she's donating his brain to "raise awareness of the clear connection between ALS and CTE" ...

PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early ...

Steve ‘Mongo’ McMichael was diagnosed with CTE nearly one year after his death. The Concussion & CTE Foundation announced ...